Bioscience Trends

(The H4-Index of Bioscience Trends is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-11-01 to 2023-11-01.)
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies1705
Drug treatment options for the 2019-new coronavirus (2019-nCoV)721
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment361
COVID-19: Real-time dissemination of scientific information to fight a public health emergency of international concern116
Challenges to the system of reserve medical supplies for public health emergencies: reflections on the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in China115
Overview of the characteristics of and responses to the three waves of COVID-19 in Japan during 2020-202168
Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China68
Analysis of COVID-19 infection spread in Japan based on stochastic transition model66
The positive role of traditional Chinese medicine as an adjunctive therapy for cancer65
Macrolide treatment for COVID-19: Will this be the way forward?46
Asymptomatic carriers of COVID-19 as a concern for disease prevention and control: more testing, more follow-up45
A review of traditional Chinese medicine for treatment of glioblastoma44
Surgical treatment of hepatocellular carcinoma43
COVID-19 vaccine research focusses on safety, efficacy, immunoinformatics, and vaccine production and delivery: a bibliometric analysis based on VOSviewer38
The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update38
Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)36
Conversion therapy and maintenance therapy for primary hepatocellular carcinoma34
Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer33
Progress on drug pricing negotiations in China33
Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database31
NEK7: a potential therapy target for NLRP3-related diseases29
Mobile field hospitals, an effective way of dealing with COVID-19 in China: sharing our experience29
New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals28
Predicting intervention effect for COVID-19 in Japan: state space modeling approach27
Systemic treatment of advanced or recurrent biliary tract cancer26